 
    Denali Ventures, an investment firm, finances companies with methods for controlling significant disease entities and medical conditions.
| 
                        Date
                        Company Name
                     | Round | Money Raised | Industry | Lead Investor | 
|---|---|---|---|---|
| 
                      May 20, 2016
                      
                            Fanplayr | Series A | $6M | Ad Targeting | — | 
| 
                      May 15, 2012
                      
                            Gamida Cell | Series E | $10M | Biotechnology | — | 
| 
                      Sep 27, 2006
                      
                            Gamida Cell | Series D | $16M | Biotechnology | — | 
| 
                      Oct 3, 2002
                      
                            HyperRoll | Series B | $12.50M | Architecture | — | 
| 
                      Oct 16, 2001
                      
                           | Series D | $30M | Biopharma | — | 
Denali Ventures has had 3 exits. Denali Ventures most notable exits include Gamida Cell , HyperRoll
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Oct 25, 2018 | Gamida Cell | IPO | Biotechnology | Detail | 
| Sep 29, 2009 | HyperRoll | M&A | Architecture | Detail | 
| Aug 17, 2009 | D Pharm LTD. | IPO | Biopharma | Detail |